AbbVie has secured a broad pediatric label for Skyrizi, adding both plaque psoriasis and active psoriatic arthritis alongside a new dose for children weighing less than 40 kg. The approval could strengthen treatment choice, although the evidence supporting the two indications is not equally direct.
Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.
Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.
A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.
FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis. Discover what TYK2 inhibition means for autoimmune treatment and future rheumatology drugs.
Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia's biosimilar adoption. Find out what this means.
Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.
STADA Arzneimittel AG and Bio-Thera Solutions have secured a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Gotenfia, a proposed biosimilar to the tumor necrosis factor alpha inhibitor golimumab. The product references Simponi, an originator drug widely prescribed for multiple autoimmune conditions. If approved, Gotenfia would be marketed